Merit Medical Systems, Inc. (MMSI)
Valor JustoFundamental
70
Precio
$86.23
Capitalización Bursátil
$5.15B
Parte 1 · Cuánto vale la empresa
Resumen
Merit Medical Systems, Inc. designs, develops, manufactures, and markets single-use medical products for interventional, diagnostic, and therapeutic procedures in the United States, China, Japan, Germany, France, the United Kingdom, and internationally. It operates through two segments, Cardiovascular and Endoscopy. The company offers micropuncture kits, angiographic needles, sheaths, guide wires, and safety products; peripheral intervention products comprising angiography, drainage, delivery systems, and embolotherapy products; oncology products, such as soft tissue biopsy products and accessories; cardiac intervention products consisting of cardiac access, angiography, electrophysiology and cardiac rhythm management, fluid management, hemodynamic monitoring, hemostasis, and intervention products; and spine products, including vertebral augmentation, radiofrequency ablation, and bone biopsy systems. It also provides custom procedural solutions, including critical care products, syringes, manifold kits, and trays and packs; coating services for medical tubes and wires; and sensor components for microelectromechanical systems. In addition, the company offers gastroenterology products, such as esophageal stents, cryoballoon and inflation devices, gauges, and balloon dilators; pulmonary products consisting of laser-cut tracheobronchial stents, and over-the-wire and direct visualization delivery systems; and kits and accessories for endoscopy and bronchoscopy procedures. It sells its products to hospitals, alternate site-based physicians, technicians, and nurses through direct sales force, independent distributors, original equipment manufacturer partners, and custom procedure tray manufacturers. The company exports its products to Canada, Western Europe, Australia, Brazil, Malaysia, South Korea, the United Arab Emirates, India, New Zealand, and South Africa. Merit Medical Systems, Inc. was incorporated in 1987 and is headquartered in South Jordan, Utah.
No editorial profile for this company yet
Direct competitors
Who this company fights with for the same customers
Generated on 19 de septiembre de 2026 with claude-haiku-4-5 — shared with all users
BD's interventional and vascular access lines compete with Merit for the same hospital purchasing contracts on catheters, ports, drainage and biopsy products.
Boston Scientific sells competing peripheral intervention, embolization and endoscopy devices, the three areas where Merit generates most of its revenue.
Merit names Teleflex first among its rivals in both peripheral and cardiac intervention, where the two sell overlapping catheters, introducers and vascular access devices to the same interventional radiology and cardiology labs.
Cook Medical, privately held, is the one competitor Merit names in every product area — peripheral intervention, cardiac intervention, oncology and endoscopy — with a directly comparable catalogue of interventional catheters, guidewires and biopsy devices.
Medtronic competes with Merit in peripheral and cardiac intervention and, through its spine business, for the OEM and implant components Merit also supplies.
Terumo is named by Merit as a cardiac intervention competitor, selling rival radial access sheaths, guidewires and inflation devices to the same catheter labs, with particular strength in Japan and Europe.
Balance y Liquidez
Ingresos
$1.58B
Últimos 12 meses (hasta 30/6/2026)
Beneficio Neto
$146M
Últimos 12 meses (hasta 30/6/2026)
Flujo de Caja Libre
$216M
Patrimonio Neto Total
$1.58B
Pasivo Total
$1.10B
Ratio de Liquidez
4.20
Cobertura de Intereses
6.34
Deuda/EBITDA
2.66
Beneficio Por Acción
Ingresos y Beneficio Neto
Flujo de Caja Libre
Desglose de Ingresos
Estado histórico
Márgenes en el tiempo
La deuda en el tiempo
Cuánto pesa la deuda
Cuadro de crecimiento
Crecimiento — Ingresos
Estimación de Valor Justo
Valor Justo
$74.75
Precio Actual
$86.23
Margen de Seguridad
-15.4%
Rango de Valor Justo
$48.58 - $100.91
Dispersión entre los métodos de valoración utilizados, no un intervalo de confianza calibrado estadísticamente.
Métodos de Estimación
Métricas de Valoración
Ratio P/E
35.49
ROE
8.1%
Ratio P/B
3.07
P/FCF
25.34
Margen Bruto
49.5%
ROIC
6.1%
Radar de Rentabilidad
Creación de Valor (Ventaja Competitiva)
ROIC
6.1%
WACC
7.3%
ROIC − WACC
-1.1 pp
El ROIC está por debajo del coste del capital: la empresa destruye valor por cada dólar invertido.
Criterios de Análisis Fundamental
Superado (21)
- EPS shows upward trend
- EPS CAGR 7.91%
- Price CAGR 12.63%
- ROIC 6.1%
- Gross Margin 49.5%
- P/FCF 25.34
- Debt/Equity ratio
- Operating Margin 12.8%
- Positive Free Cash Flow
- Current Ratio
- Interest Coverage
- Debt/EBITDA
- Return on Tangible Assets
- ROE 9.1%
- Revenue Growth 5Y 9.5%
- Analyst Consensus 82% Buy
- Earnings Surprise avg 11.9%
- Earnings Quality (OCF/NI) 1.95
- Share Dilution 1.7%
- Net Margin Trend 9.2% vs 8.3%
- Piotroski F-Score 7/9
Fallido (5)
- P/B Ratio 3.07
- CapEx intensity
- Low reliance on intangibles
- Price below Graham Number
- DCF valuation (Overvalued)
No disponible (2)
- Dividend Payout NaN%
- PEG Ratio (need PE > 0 and growth > 0)
Piotroski F-Score
Solidez financiera fuerte
Calidad de los Beneficios
Alta calidad: beneficios respaldados por efectivo
Dilución de Acciones
El número de acciones es estable
Participaciones institucionales
Gobernanza
Equipo Directivo
| Nombre | Cargo | Edad |
|---|---|---|
| Ms. Martha Goldberg Aronson | President, CEO & Director | 58 |
| Mr. Raul Parra Jr., CPA | CFO & Treasurer | 46 |
| Mr. Brian G. Lloyd J.D. | Chief Legal Officer & Corporate Secretary | 64 |
| Mr. Michel J. Voigt | Chief Human Resources Officer | 52 |
| Mr. Neil W. Peterson | Senior Advisor | 59 |
| Mr. Jason Treft | Chief Information Officer | - |
| Ms. Sarah Comstock | Vice President of Global Communications | - |
| Mr. John Knorpp | Chief Regulatory Affairs Officer | - |
| Mr. Ricardo Alvarez | Managing Director of Operation Merit Medical Tijuana | - |
| Mr. Mark Butler | Executive Vice President of Merit Medical EMEA | - |
Riesgo de Auditoría
2
Riesgo del Consejo
2
Riesgo de Compensación
1
Riesgo de Derechos del Accionista
4
Parte 2 · El precio y el momento de entrar
Esta parte no sirve para saber si la empresa vale: sirve para elegir cuándo comprarla, una vez que los fundamentales te han convencido. Dentro: análisis técnico, potencial, caídas históricas, exposición gamma.
Documentos
- Ver documento
Informe anual (10-K)
Un resumen anual del negocio, los resultados financieros y los riesgos de la empresa.
Presentado el 2026-02-24
- Ver documento
Informe trimestral (10-Q)
Una actualización del desempeño financiero de los últimos tres meses.
Presentado el 2026-07-30
- Ver documento
Informe de hecho relevante (8-K)
Un aviso sobre un hecho relevante, como un cambio de dirección o un anuncio importante.
Presentado el 2026-08-20
via SEC EDGAR
Historial de Resultados
via SEC EDGAR
Latest News
Recent headlines for MMSI, sourced from Markets Gazette.